Jubilant Pharma Limited, through one of its units Jubilant DraxImage Inc (JDI) headquartered in Montreal (Canada), has received approval from TGA, Australia for lyophilised kit for the preparation of Technetium 99m Macro-Aggregated Albumin (MAA) injection. Jubilant Pharma Limited is the wholly owned subsidiary of Jubilant Life Sciences Ltd.
Technetium 99mTc albumin MAA is an injectable radiopharmaceutical used in nuclear medicine.
MAA provides accurate scans to assess lung perfusion and rule out pulmonary embolism with low radiation exposure. JDI is the leading supplier of MAA in the US and has approval in four other countries including Canada, Columbia, Hong Kong and Israel. The Australian MAA product is expected to be launched as part of Jubilant DraxImage’s larger commitment to investing in the growth and robust sustainability of Nuclear Medicine globally and cater to the needs of suspected pulmonary embolism patients.
